Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Relapsed, refractory CNS lymphoma, ocular lymphoma, lymphomatous meningitis~2. Tumors must be CD20 + on pathologic analysis.~3. Patients must have an Ommaya reservoir (ventricular access device.~4. Patients may have had prior intrathecal methotrexate, ara-C or thiotepa but must have recovered from any reversible toxicity caused by prior treatment.~5. Concurrent systemic chemotherapy is allowed for treatment of disease outside the meninges with the exception of high-dose methotrexate (\>500 mg/m2/d, high-dose ara-C (\> 2 gm/m2/d), high-dose thiotepa (\>300 mg/m2/d) or investigational agents.~6. Patients must have sufficient baseline hematologic function: \>1,500 granulocytes and \>50,000 platelets/ul.~7. Patients must have had a nuclear medicine CSF flow study performed within 30 days of treatment which shows no significant obstruction within the ventricles.~Exclusion Criteria:~1. History of whole brain or craniospinal irradiation or intrathecal chemotherapy \< 4 days before initiation of intra-CSF administration of rituximab.~2. Anticipated survival of less than one month.~3. HIV infection. -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab Plus MTX (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).